Each month, the editors at SearchHealthIT recognize an innovative software, service or technology approach. Glytec's diabetes management software system is our January 2017 selection.
By submitting your personal information, you agree that TechTarget and its partners may contact you regarding relevant content, products and special offers.
Product: eGlycemic Management System
Release date: First approved by FDA in 2006
What Glytec does
This company's cloud-based diabetes management system is called eGMS, short for eGlycemic Management System.
The diabetes management software system is made up of a suite of modules that helps providers improve insulin dosing for the care of patients with acute diabetes, hypoglycemia and hyperglycemia.
The eGMS diabetes management software system is built around the Glucocommander set of FDA-approved proprietary dosing algorithms for intravenous, subcutaneous and pediatric administration of insulin.
The system contains clinical decision support tools and can be integrated with connected medical devices such as blood glucose meters, as well as EHRs. It also comes with analytics and surveillance modules.
While the company, since its first FDA-approved insulin dosing system was released in 2006, has focused on acute, inpatient care, in the last two years it began to expand the use and marketing of its products in the outpatient market with the advent of Bluetooth and wireless glucose meters.
Glytec, based in Greenville, S.C., is aimed mostly at managing insulin dosage for patients with acute hyperglycemia, which results not only from diabetes but also frequently from surgery-induced physiological stress or post-surgery medication problems.
But Glytec diabetes management software systems can also monitor and manage treatment regimens for patients with chronic, type 2 diabetes, only about 25% of whom are on insulin but who make up a huge population of from 6 to 10 million diabetes patients, Robby Booth, senior vice president for R&D at Glytec, noted.
Why Glytec matters
Glytec said it bases its technology on evidence-based research, and that providers that use its system can significantly cut the frequency, risks and costs of hypoglycemia and hyperglycemia, including reducing length of hospital stays and increasing quality of life.
"With insulin being one of the most dangerous drugs, it's a big problem getting patients the right dose," Booth said. "It's a very personalized therapy."
Robby Boothsenior vice president for R&D, Glytec
Glytec's algorithms churn through the data returned to its cloud from the patient-connected devices and make recommendations to care providers, and those recommendations are automatically pushed back into the EHR.
The Glytec system is automating the cumbersome paper or manual chore that nurses have long been saddled with of determining the correct insulin dosage for each patient at the right time.
"Not only are we providing better insulin doses for these patients, we're also trying to reduce the amount of work that nurses have to do," Booth said. "You can make the workflow not only more effective but also more efficient."
Like so many health IT companies these days, Glytec is intensely aware of the transition to value-based care and how important it is to help providers treat in coordinated fashion the most chronically ill and high-risk patients. Diabetes, of course, is one of the most expensive diseases, in both its acute and chronic forms.
"The folks costing the most money are the ones you want to engage with a team," said Dr. Andrew Rhinehart Glytec's chief medical officer. "You need the providers, but you also need the educators, you need the connected devices, you need our algorithms to help titrate (determine the concentration of a solution) the insulin to put this all together to help manage these very difficult patients."
What a user says
Paul Chidester, M.D., vice president of medical affairs at Sentara Norfolk General Hospital in Virginia, has overseen a Glytec application at his hospital and its healthcare system, Sentara Health, for nearly five years.
The Glytec diabetes management program is being used, primarily by frontline nurses, at 12 Sentara hospitals and the healthcare system plans to install it in two more soon. At Sentara Norfolk, which admits about 25,000 patients a year, as many as 6,000 are diabetic and on the Glytec system, Chidester said.
"This work with Glytec has just been driven off of our desire to improve clinical outcomes" for diabetic patients, Chidester said. "We've seen a really nice reduction in hypoglycemic events across our system. We really see very few hypoglycemic events associated with patients who are on Glucommander."
Glucommander is the heart of the Glytec diabetes management software system in both its inpatient and outpatient incarnations.
Revolving around Glucommander are its Glycloud host, the GlucoMetrics analytics system to gauge glycemic control performance throughout a health system, the SmartClick EHR and connected device integration tools, and GlucoSurveillance for patient risk identification.
Once blood sugar values are saved to the secure, HIPAA-compliant Glycloud, Glucommander analyzes the data and produces accurate mealtime insulin dosages.
Software as a service pricing varies for this diabetes management software by the scope of deployment and size of the healthcare organization.
IBM Watson Health and Medtronic partner to combat diabetes
EHR vendors using advanced analytics
The shift to value-based care as seen by an expert